Objective: This study analyzed which definition of the metabolic syndrome (MetS) is more predictive of cardiovascular events in both diabetic and non-diabetic members of a population based sample.
The metabolic syndrome represents clusters of cardiovascular risk factors, assuming that cardiovascular risk is amplified more than expected from the effect of single risk factors 1 . Many studies support the utility of this definition 2,3 , but others have questioned the incremental utility of this approach 4 .
An element of potential confusion concerning the real prognostic utility of defining metabolic syndrome is the availability of several definitions [5] [6] [7] [8] [9] , reflecting different strategies, either identifying a main characteristic as a necessary factor 5, 7, 9 associated with other variable risk factors, or accepting varied combinations of characteristics 6, 8 . Other differences may also be important, including partition values and methods to define abnormalities.
At present, few data exist comparing the correlates and prognostic significance of the definitions of metabolic syndrome in the same population. Accordingly, we compared the ability of the most used definitions of metabolic syndrome to predict cardiovascular events in the Strong Heart Study cohort.
RESEARCH DESIGN AND METHODS
Population: The Strong Heart Study (SHS) is a population-based cohort study of cardiovascular risk factors and disease in 4,549 American Indians from 3 communities in Arizona, 7 in Southwestern Oklahoma and 3 in South and North Dakota, extensively described [10] [11] [12] [13] [14] . Participants seen during the baseline exam, in 1989 to 1992 were representative of the source population 15 .
For the present analysis, individuals with prevalent cardiovascular disease (n=287, 127 women) were excluded. Prevalent and incident cardiovascular events (cardiovascular death, stroke, congestive heart failure, myocardial infarction, coronary heart disease [coronary angiography or combination of typical symptoms with positive treadmill tests or abnormal imaging stress test, or revascularization procedures]) were confirmed by the Strong Heart Study Mortality and Morbidity Committees, using specified criteria for causes of fatal and nonfatal cardiovascular events 16 . Diabetic participants were included; participants with fasting triglyceride levels>750 mg/dL were excluded. Thus, 3,945 participants (2,384 women) without prevalent cardiovascular disease and available data (1,700 with diabetes; 1,468 with hypertension) were included in the analysis.
Laboratory tests and definitions of metabolic syndrome: Fasting plasma glucose and lipid profile were measured by standard methods 12 . Diabetes (≥126 mg/dL or antidiabetic treatment) and impaired fasting glucose (≥110 mg/dL) were diagnosed by 1997 American Diabetes Association recommendations 17 . Obesity was classified based on the 1998 NIH guidelines 18 (BMI≥30 kg/m 2 ). Central fat distribution was based on waist circumference and defined in relation to sex-specific cutoff points used in the different definitions examined in this study ( Ten-year relative risk of combined fatal and non-fatal cardiovascular events was estimated for each definition. Log-cumulative hazard functions were computed by Cox regression adjusting for age (years), field center, sex and diabetes. Additional models were also adjusted for the other components of metabolic syndrome. Cox regression was also run separately for diabetic and nondiabetic participants.
To compare the independent prognostic effect of metabolic syndrome by the 3 definitions, likelihood functions were compared 20 . The difference between two -2 log likelihoods has a χ² distribution, which, for this comparison, has 1 degree of freedom 20 . Two-tailed α≤0.01 identified significant differences among the 3 models. Table 2 shows that the IDF definition yielded the highest prevalence of metabolic syndrome in both men and women. The WHO definition resulted in a similar proportion of metabolic syndrome in men and women, whereas ATPIII and IDF showed a substantially higher prevalence in women, with the greatest sexdifference by ATPIII definition (both p<0.0001). The coefficient of concordance (k) among the different definitions in the recognition of metabolic syndrome status was not excellent, being 0.56 and 0.59 for men and women between WHO and ATPIII, 0.58 and 0.77 between ATPIII and IDF, and only 0.49 and 0.50 between WHO and IDF definitions.
RESULTS
Table 2 also shows that, due to differing high blood pressure criteria, the WHO definition was associated with slightly higher blood pressure levels than ATPIII or IDF. Urinary albumin/excretion ratio was highest in participants with metabolic syndrome by WHO definition (including this parameter among criteria for definition), but also higher in the ATPIII and IDF definitions (all p<0.0001) than in participants without metabolic syndrome.
The criteria for adiposity proposed by the WHO identified 83% of participants with central fat distribution in the absence of metabolic syndrome (compared to 96% in those with metabolic syndrome). The difference between groups without (66% with central fat) vs with metabolic syndrome (100%) was more accentuated in the IDF, and maximal with the ATPIII definition (50 vs. 91%, respectively). In all definitions, half or more of individuals free of the syndrome exhibited central fat distribution.
Cardiovascular risk in the metabolic syndrome.
Over the follow-up time (119±45 months), 1,157 cardiovascular events were adjudicated, including 176 strokes, 299 myocardial infarctions, 226 other clinical manifestations of coronary heart disease, 394 congestive heart failure and 62 sudden deaths. The incidence of combined fatal and non-fatal cardiovascular events was 2.38-fold greater in participants with than in those without metabolic syndrome (95% C.I.=2.04-2.73) by WHO definition, 2.12-fold greater (95% C.I.=1.81-2.47) by ATPIII definition and 1.92-fold greater (95% C.I.=1.62-2.27) by IDF (all p<0.0001). Table 3 Cardiovascular risk in diabetic and nondiabetic subjects.
Both in diabetic and non diabetic participants the prognostic effect of metabolic syndrome was confirmed for all three definitions (table 4). The hazard for incident composite fatal and non fatal events was about 30-40% higher in non-diabetic participants with metabolic syndrome, by all definitions, without significant difference among them (figure 1). In contrast, in diabetic participants, the hazard ratio for the metabolic syndrome was not statistically significant using the IDF definition (26% increased risk), higher with ATPIII definition (43% increased risk) and the highest with the WHO definition (near doubled risk), a difference that was statistically significantly (p<0.001).
DISCUSSION
This study demonstrates that in the Strong Heart Study cohort, metabolic syndrome by all three examined definitions is independently associated with a significantly greater rate of incident composite fatal and non fatal cardiovascular events and a marker of preclinical cardiovascular disease, represented by the increased urinary albumin/creatinine excretion. The independent association of metabolic syndrome with cardiovascular events was seen in population strata with or without diabetes.
In participants without diabetes, increased cardiovascular risk is independently associated with metabolic syndrome, suggesting that this diagnosis can help identify high risk individuals. Similarly, among diabetic individuals, recognition of the metabolic syndrome enhanced impressively the prediction of cardiovascular events, consistent with NHANES-III results 21 , where the age-adjusted prevalence of coronary heart disease in the diabetic population without metabolic syndrome (8%) was similar to that in subjects without diabetes or metabolic syndrome (9%), whereas increasing to 14% in non-diabetic subjects with metabolic syndrome, and to 19% in those with both conditions. However, independent of the presence of full-fledged metabolic syndrome, attention to all cardiovascular risk factors is paramount in the presence of diabetes. As compared to non-diabetic populations, detecting the full presentation of metabolic syndrome might be less important for decision making when diabetes coexists with even one additional risk factor. This study identifies similarities among the three definitions of metabolic syndrome but also reveals differences. In the whole population, combining participants with or without diabetes, the model using the WHO definition was a better predictor than models using ATPIII or IDF definitions, with IDF exhibiting the lowest fit. When forcing single cardiovascular risk factors into the proportional hazard model, only WHO and ATPIII definitions maintained an independent prognostic impact, whereas IDF definition did not, possibly due to lower specificity associated with the generally lower partition values for single factors.
In non-diabetic participants, the risks predicted by the three definitions were not statistically different.
In contrast, a substantial difference was evident among diabetic participants, with the WHO definition significantly superior to both ATPIII and IDF (the hazard ratio of which was not statistically significant). Although the ATPIII definition was not intended for diabetic individuals, it should be noted that it performed well in participants with or without diabetes, though slightly less well than WHO in those with diabetes.
To evaluate correctly the implications of these findings, both the characteristics of the Strong Heart Study population and the differences among the different definitions of metabolic syndrome have to be taken into account. The American Indian population of the Strong Heart Study is characterized by higher prevalences of obesity than the overall population in US and in Europe 12 , though this difference is rapidly attenuating [22] [23] [24] [25] . As a consequence, in the Strong Heart Study cohort, the distribution of measures of adiposity is skewed toward higher values, similar to findings in hypertensive populations 26 . Due to the high prevalence of obesity, the adopted measures of fatness in the WHO definition do not discriminate well between participants with or without the metabolic syndrome. Also with the other definitions, substantial proportions of participants without metabolic syndrome exhibited central fat distribution, maximal with the IDF definition, which uses very low partition values for waist girth. Thus, in the context of a population with very high prevalence of obesity, measures of adiposity or abdominal obesity do not strongly separate individuals with or without metabolic syndrome, since obesity is also highly prevalent among individuals without metabolic syndrome.
The present analysis extends a previous study of metabolic syndrome in nondiabetic SHS participants. That analysis did not report significant independent associations between metabolic syndrome (by ATPIII) and cardiovascular risk 27 , but it included only 4.2 years of follow-up and was limited to some cardiac events. In contrast, the present analysis included also diabetic participants, the follow-up was substantially longer, and all clinical manifestations of cardiovascular disease, including cerebrovascular events and congestive heart failure, were considered as end-points. In particular, incident congestive heart failure (394 adjudicated events) could be very important, because heart failure is a relevant end point for obesity [28] [29] [30] . Overall, our findings suggest that the metabolic syndrome may take several years to manifest its effects on clinical events (as also figure 1 suggests).
In conclusion, ATPIII and WHO (but not IDF) definitions of metabolic syndrome predict cardiovascular disease independently of single components of the syndrome; their value may be similar in individuals without diabetes, but in diabetes the WHO definition seems to be more useful. Results of these analyses, obtained in a population with high prevalences of obesity and diabetes are likely applicable to other populations of different ethnicities in which there is an epidemic rise of prevalence of overweight and obesity 31 , triggering diabetes and other metabolic abnormalities 32 . The identification of the metabolic syndrome can be valuable to focus aggressive intervention strategies, especially when diabetes has not yet occurred.
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